Medindia

X

CoDa Therapeutics Achieves Positive Phase 2 Efficacy of NEXAGON® in Chronic Venous Leg Ulcers

Tuesday, May 25, 2010 General News J E 4
Advertisement
69% Reduction in Venous Leg Ulcer Size in High-Dose Arm at 4 Weeks

For More Information, please contact:

CoDa Therapeutics Inc.

Bradford Duft, President and CEO (brad@codatherapeutics.com)

David Pool, CFO (david@codatherapeutics.com)

The Ruth Group (on behalf of CoDa Therapeutics in the US)

Sara Pellegrino – Investors (646-536-7002 / spellegrino@theruthgroup.com)

Jason Rando – Media (646-536-7025 / jrando@theruthgroup.com)

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
The Irish Government and the Irish Voice Recognize...
S
Here Comes Summer and Your Children Need Serious E...